Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 38

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 38
---
 issuance under the Scilex Holding Company 2022 Employee Stock Purchase Plan (the “ESPP”); |

| • |     | up to 40,000 shares of Common Stock available for future issuance under the Scilex Holding Company 2023 Inducement Plan (the “Inducement Plan”); |

| • |     | up to 6,958,309 SPAC Warrants (on a pre-Reverse Stock Split basis), which are currently exercisable for an aggregate of up to 198,810 shares (on a post-Reverse Stock Split basis) of Common Stock, with an exercise price of $402.50 per whole share; and |

| • |     | 6,500,000 shares of Common Stock issuable upon the exercise of the Penny Warrants, with an exercise price of $0.01 per share. |

22

RISK FACTORS Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section of this prospectus titled “Cautionary Note Regarding Forward-Looking Statements”. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein. Risks Related to our Limited Operating History, Financial Condition and Capital Requirements We currently have three commercial products, ZTlido, ELYXYB and GLOPERBA; but we are currently heavily dependent on the commercial success of ZTlido, as ELYXYB and GLOPERBA are in the initial stages of commercialization, and we may be unable to generate sufficient revenue to support our operations. We currently have three commercial products, ZTlido, ELYXYB and GLOPERBA; but we are currently heavily dependent upon ZTlido sales to generate revenue, as ELYXYB and GLOPER